Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients

Affiliations

¹ Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
² TriNetX LLC, Cambridge, MA, USA.
³ Center for Biomedical Informatics, Clinical and Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
⁵ Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
⁶ Medical College of Wisconsin Medical School, Milwaukee, WI, USA.
⁷ Division of Hematology, University of Utah, Salt Lake City, UT, USA.
⁸ Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Myeloma, Waldenstrom's, and Amyloidosis Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
¹¹ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹² Department of Internal Medicine, University Hospital of Würzburg, Würzburg, Germany.
¹³ Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
¹⁴ Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. memohan@mcw.edu.

^# Contributed equally.

Farheen Chunara et al. Blood Cancer J. 2025.

. 2025 Apr 8;15(1):61.

doi: 10.1038/s41408-025-01254-4.

¹ Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
² TriNetX LLC, Cambridge, MA, USA.
³ Center for Biomedical Informatics, Clinical and Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
⁵ Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
⁶ Medical College of Wisconsin Medical School, Milwaukee, WI, USA.
⁷ Division of Hematology, University of Utah, Salt Lake City, UT, USA.
⁸ Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Myeloma, Waldenstrom's, and Amyloidosis Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
¹¹ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹² Department of Internal Medicine, University Hospital of Würzburg, Würzburg, Germany.
¹³ Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
¹⁴ Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. memohan@mcw.edu.

^# Contributed equally.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. - DOI - PMC - PubMed
1. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodríguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232–44. - DOI - PubMed
1. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, et al. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood Cancer J. 2024;14:137. - DOI - PMC - PubMed
1. Tan CRC, Derkach A, Maclachlan K, Hultcrantz M, Hassoun H, Mailankody S, et al. Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:7536. - DOI
1. Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35. - DOI - PMC - PubMed